Sichuan Hebang Biotechnology Corporation Limited
603077.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CN¥9 | CN¥9 | CN¥13 | CN¥10 |
| % Growth | -3.1% | -32.3% | 30.6% | – |
| Cost of Goods Sold | CN¥8 | CN¥7 | CN¥7 | CN¥6 |
| Gross Profit | CN¥1 | CN¥2 | CN¥6 | CN¥4 |
| % Margin | 6.3% | 22.7% | 42.5% | 41.2% |
| R&D Expenses | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| G&A Expenses | CN¥0 | CN¥0 | CN¥1 | CN¥0 |
| SG&A Expenses | CN¥0 | CN¥0 | CN¥1 | CN¥0 |
| Sales & Mktg Exp. | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other Operating Expenses | CN¥0 | -CN¥0 | CN¥0 | CN¥0 |
| Operating Expenses | CN¥1 | CN¥0 | CN¥1 | CN¥1 |
| Operating Income | -CN¥0 | CN¥2 | CN¥4 | CN¥4 |
| % Margin | -0.7% | 17.5% | 34.4% | 36% |
| Other Income/Exp. Net | -CN¥0 | -CN¥0 | -CN¥0 | -CN¥0 |
| Pre-Tax Income | -CN¥0 | CN¥2 | CN¥4 | CN¥4 |
| Tax Expense | CN¥0 | CN¥0 | CN¥1 | CN¥1 |
| Net Income | CN¥0 | CN¥1 | CN¥4 | CN¥3 |
| % Margin | 0.4% | 14.5% | 29.2% | 30.2% |
| EPS | 0.004 | 0.147 | 0.438 | 0.358 |
| % Growth | -97.4% | -66.3% | 22.3% | – |
| EPS Diluted | 0.004 | 0.147 | 0.438 | 0.358 |
| Weighted Avg Shares Out | 8 | 9 | 9 | 8 |
| Weighted Avg Shares Out Dil | 9 | 9 | 9 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Interest Expense | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Depreciation & Amortization | CN¥1 | CN¥1 | CN¥1 | CN¥1 |
| EBITDA | CN¥1 | CN¥2 | CN¥5 | CN¥4 |
| % Margin | 10.8% | 27.3% | 41.4% | 42.9% |